EVER PHARMA

STROKE

TBI

DEMENTIA

Lang et al., 2013

Early recovery with Cerebrolysin

Effective pharmacological treatment for **STROKE** patients

A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke
Lang et al., International Journal of Stroke (2013) Vol 8, 95–104

Cerebrolysin®

Reconnecting Neurons.
Empowering for Life.

Start Cerebrolysin therapy immediately after stroke

Cerebrolysin boosts early recovery after stroke

→ Cerebrolysin + rtPA therapy results in earlier recovery than rtPA alone

→ Patients are able to get out of bed earlier

→ Earlier start with rehabilitation possible

→ Fast progress motivates patients



Figure 1: Responder analysis - Evolution of NIHSS[1] responders
A responder was defined as a patient who improved by at least 6 points from baseline, or whose total score was 0 or 1

- **Significant earlier responses** in the Cerebrolysin + rtPA group on day 2, 5, 10 and 30
- Differences reached its maximum **(+77%) at day 5** with a responder rate of 66.1% in Cerebrolysin group vs. 37.3% in group treated with rtPA alone
- Cerebrolysin shifts the day 90 responder rate **forward to day 10**
- **Combination therapy rtPA + Cerebrolysin is safe and well tolerated**

Titel	A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke
Patients	60 Cerebrolysin group + 59 placebo group = 119 patients in total Patients from 14 hospitals in 5 European countries Cerebrolysin group = Cerebrolysin + rtPA Placebo group = Saline + rtPA
Treatment	Treatment initiation after 1 hr of rtPA 30ml/day for 10 days Primary endpoint = NIHSS[1] and mRS[2] on day 90

[1]NIHSS = National Institutes of Health Stroke Scale
[2]mRS = modified Rankin Scale

ABBREVIATED PRESCRIBING INFORMATION. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.

CERE/INT/11/2017/16